Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse

P. Boddu, J. Jorgensen, H. Kantarjian, G. Borthakur, T. Kadia, N. Daver, Y. Alvarado, N. Pemmaraju, P. Bose, K. Naqvi, M. Yilmaz, S. Pierce, M. Brandt, C. D. DiNardo, E. J. Jabbour, M. Konopleva, G. Garcia-Manero, J. Cortes, F. Ravandi

Research output: Contribution to journalLetter

12 Scopus citations
Original languageEnglish (US)
Pages (from-to)241-244
Number of pages4
JournalLeukemia
Volume32
Issue number1
DOIs
StatePublished - Jan 2018
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Boddu, P., Jorgensen, J., Kantarjian, H., Borthakur, G., Kadia, T., Daver, N., Alvarado, Y., Pemmaraju, N., Bose, P., Naqvi, K., Yilmaz, M., Pierce, S., Brandt, M., DiNardo, C. D., Jabbour, E. J., Konopleva, M., Garcia-Manero, G., Cortes, J., & Ravandi, F. (2018). Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse. Leukemia, 32(1), 241-244. https://doi.org/10.1038/leu.2017.285